Introduction
Results of a genome-wide search in inflammatory bowel disease (IBD) provided evidence that there may be susceptibility genes on chromosomes 3, 7 and 12. 1 One of the candidate genes lying close to the linked region on chromosome 7 is the gene encoding interleukin 6, 2 which is a multifunctional cytokine synthesised by both lymphoid and non-lymphoid cells. In IBD, the activated monocytes, macrophages and epithelial cells all produced interleukin-6 (IL-6), 3 which has many pertinent biological activities including B cell differentiation, stimulation of immunoglobulin secretion, induction of T cell proliferation and acute phase protein production by hepatocytes. 4 IL-6 is thus a strong candidate for an IBD susceptibility gene.
The human IL-6 gene is approximately 5 kb in length and consists of five exons and four introns. 5 Allelic variation has been described in the 3Ј flanking region of the gene due to the insertion of a variable number of AT tandem repeats (VNTR). This system has been previously studied, both by restriction fragment length polymorphism (RFLP) 6 and by amplification of the IL-6 VNTRs and fractionation on agarose gels. 7, 8 Here we have developed a polymerase chain reaction with sequence-specific primers (PCR-SSP) system to detect a new biallelic G to A polymorphism in the 4th intron of the IL-6 gene, which is relevant to the reported MspI restriction enzyme polymorphism. 9 Following evidence from genetic and functional studies on the relevance of IL-6 to IBD we have studied both the distribution of IL-6 polymorphisms and their functional effects in IBD patients and healthy controls in an attempt to relate production of IL-6 to individual polymorphisms as well as to ascertain whether any of these polymorphisms are associated with IBD.
Results

IL-6 allele frequencies
Genotype and allele frequencies of the IL-6 4470*G/A biallelic polymorphism in the 4th intron and the VNTR polymorphism in 3Ј flanking region of the IL-6 gene were studied in 88 Crohn's disease (CD), 104 ulcerative colitis (UC) patients and 225 healthy controls. Allele IL-6*G was found to be more frequent in CD patients (50%) than in healthy controls (39.8%; P = 0.025). No other significant difference in genotypes or allele frequencies for examined polymorphisms were observed between those groups examined. Although not statistically significant allele IL-6*G was also more frequent in UC patients when compared to controls (46.1% vs 39.8%) ( Table 1) .
IL-6 protein production in subgroups of healthy controls and patients
Since steroids have been shown to suppress the IL-6 release from circulating mononuclear cells, 10, 11 therefore, IL-6 protein production was only measured in IBD patients that had not received steroid treatment for at least a month prior to assay. Plasma IL-6 level was measured in duplicates in 44 healthy controls, 32 CD and 35 UC patients. Liposaccharide (LPS)-stimulated IL-6 protein production in whole blood samples was higher in healthy controls (41.9 ± 9.7 ng/mL) than in UC patients (33.2 ± 11.3 ng/mL; P = 0.01) and CD patients (30.3 ± 11 ng/mL; P = 0.02). These proportions were preserved when stimulated IL-6 plasma concentrations were corrected for the total number of monocytes.
Effect of gender:
Stimulated blood samples from healthy males produced more soluble IL-6 protein than from healthy females (44.3 ± 9.4 ng/mL vs 37.6 ± 8 ng/mL; P = 0.019). The same tendency was observed in CD males compared to females (35.3 ± 12.4 ng/mL vs 27.3 ± 9.2 ng/mL; P = 0.044). However, when the stimulated IL-6 plasma level was corrected for the total number of monocytes, no significant differences were observed between males and females.
Effect of smoking:
No differences in stimulated IL-6 production were observed between smokers and nonsmokers in the group of IBD patients or healthy controls. When, however, the stimulated IL-6 plasma level was recalculated for the total number of monocytes, smoking was associated with higher IL-6 production in CD patients (P = 0.045).
Effect of disease activity, localisation, surgery, extraintestinal manifestation:
In Crohn's disease affecting the colon, stimulated IL-6 production was higher than when the disease was limited only to the small bowel (37.4 ± 6.6 ng/mL vs 22.3 ± 11 ng/mL; P = 0.049). The higher IL-6 production in these CD patients was also accompanied by higher numbers of monocytes in blood samples (0.59 ± 0.14 × 10 9 /L vs 0.49 ± 0.14 × 10 9 /L). When stimulated IL-6 plasma levels were corrected for the total number of monocytes, there was no association seen with location of disease. In UC patients with proctitis compared to extensive disease the number of monocytes in blood samples was lower (0.44 ± 0.12 × 10 9 /L vs 0.52 ± 0.13 × 10 9 /L). However, no differences were observed in IL-6 production according to UC location. No significant differences in stimulated IL-6 production were observed in subgroups of patients defined by disease activity, need for surgery or presence of extraintestinal manifestations.
IL-6 polymorphisms and IL-6 protein production
No significant differences in stimulated IL-6 protein production (whether related to the total number of monocytes or not) were observed between individuals with differing biallelic IL-6*G/A or VNTR IL-6 polymorphisms ( Table 2) .
Relationship between IL-6 protein production and tumour necrosis factor-alpha (TNF␣) or IL-10 protein production A correlation was observed in healthy individuals between stimulated IL-6 and TNF␣ production (r = 0.441, P = 0.0021) and also between IL-6 and IL-10 production (r = 0.385, P = 0.0082). We have not observed any correlation between IL-6 and IL-10 or TNF␣ production in UC patients. In CD patients the correlation between stimulated IL-6 and IL-10 was preserved (r = 0.465, P = 0.0146).
Discussion
The present study provides evidence that the IL-6 gene is involved in determining susceptibility and disease Table 2 Functional effect of biallelic G/A polymorphism in the 4th intron of IL-6 and IL-6 VNTR polymorphism on IL-6 protein production in whole blood samples stimulated with 10 g/mL LPS for 24 h. Ulcerative colitis (UC) and Crohn's disease (CD) patients were not undergoing any steroid treatment for at least a month prior to assay (17) phenotype in Crohn's disease patients. A modest increase in the frequency of the less common IL-6*G allele was noted in Crohn's disease when compared to ulcerative colitis patients and healthy controls. However, using LPS-stimulated whole blood samples from healthy controls and IBD patients we were unable to find any effect of biallelic G to A polymorphism in the 4th intron or VNTR polymorphism in the 3Ј flanking region of the IL-6 gene on IL-6 protein production. We postulate that the IL-6 polymorphisms investigated here may be in linkage disequilibrium with a susceptibility gene and that they may be utilised as genetic markers in CD. A recent study has shown that there is a genetically determined difference in the degree of the IL-6 response to stressful stimuli between individuals and that the G/C polymorphism in the 5Ј flanking region may determine production of plasma IL-6.
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Several groups have reported that circulating IL-6 concentrations are higher in Crohn's disease compared with ulcerative colitis patients or healthy controls. [13] [14] [15] [16] Other studies have shown that IL-6 production by isolated monocytes in vitro, both spontaneously and after LPS stimulation, is similar in IBD patients and healthy controls. 10, 17 When these results were re-analysed accounting for the number of monocytes per 10 ml, the stimulated IL-6 production was increased in CD compared to UC and healthy controls. 17 We were unable to confirm any of these observations since our results showed marginally lower IL-6 production in CD patients. The more likely explanation is a methodological one. Our use of a whole blood system to study cytokines produced by a variety of cells is possibly the closest to the in vivo situation and the results reflect the biological complexity of cytokine and cell network interactions. Such network control may not be exerted in the isolated cell populations studies by others. A further potentially confounding factor is the use of a single stimulus, namely LPS. Although this is a highly relevant stimulus for both UC and CD, it is likely that other stimuli, exerting either an up-regulatory or down-regulatory effect on IL-6 production, exist in vivo.
We have shown that stimulated IL-6 production in whole blood samples from healthy individuals and CD patients is higher in males than in females. This observation is in agreement with previous reports showing that IL-6 secretion by bone marrow cells is suppressed by ovarian hormones (oestrogen). 18, 19 However, when results were re-expressed in relation to the total number of monocytes, the differences between males and females were not significant in our study.
It is well known that the production of IL-6 is regulated by a variety of molecules such as IL-1, TNF␣, IL-2, INF␤ and PDGF, which induce its production. [20] [21] [22] [23] [24] [25] In contrast, IL-4, IL-10 and IL-13 inhibit IL-6 production in monocytes. 26, 27 On the other hand IL-6 inhibits IL-1 and TNF␣ and, like IL-1 and TNF␣, it is able to stimulate IL-10 production by macrophages in vitro. 28, 29 We were able to support some of these observations in a whole blood assay. We did find correlations between IL-6 and IL-10 production and between IL-6 and TNF␣ production following LPS stimulation in healthy individuals. However in UC such correlation was absent suggesting some specific interference with the cytokine interactions in the disease. In CD the TNF␣ IL-6 correlation was again absent but correlation between IL-6 and IL-10
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In conclusion, these preliminary data suggest that there may be an association between IBD, especially CD, and an IL-6 polymorphism. This awaits confirmation in a larger and independent data set.
Materials and methods
Subjects
A group of 104 UC and 88 CD patients with no family history of IBD was randomly selected from Caucasian adult patients attending the Gastroenterology Clinic at the John Radcliffe Hospital in Oxford. Clinical data was obtained by questionnaire, personal interviews and review of case records. The diagnosis of Crohn's disease or ulcerative colitis was made on the basis of clinical, radiological and histopathological data, according to standard criteria. UC disease activity was assessed using the Sutherland score, 30 whereas Crohn's disease activity index (CDAI) 31 helped define CD patients. The extent of disease was defined using the most resent investigations (barium enema or colonoscopy) and was classified in UC patients as 'extensive' when it was proximal to the splenic flexure or as 'distal' when it was distal to the splenic flexure. Three patients with 'indeterminate' colitis were excluded from this study. Demographic data and clinical characteristics of patients with inflammatory bowel disease are summarised in Table 3 . Less than 5% of these patients were of Jewish ancestry. A group of 225 unrelated UK controls: 56 healthy individuals (26 females; 30 males) belonging to the Oxfordshire population and 169 cadaver donors (69 females; 100 males) from the Oxford Transplant Centre, Churchill Hospital served as controls. No two members from one family were included. On the afternoon of blood sampling, all healthy individuals had normal oral temperature and had not undergone intensive physical exercise in the previous 24 h.
Whole blood stimulation and DNA extraction
Four and a half millilitres of peripheral venous blood were collected into siliconised 'Vacutainer' tubes containing 0.105 m sodium citrate. Whole blood was incubated at 37°C in 5% CO 2 for 24 h with 10 g/ml of LPS (E. coli serotype 055:B5). All samples were gently inverted during incubation. Plasma was separated from whole blood cultures following stimulation for 24 h and stored at −70°C until assayed by ELISA. DNA from the remaining white blood cells was extracted using a conventional proteinase K (Boehringer Mannheim, Mannheim, Germany) digestion of isolated cells, followed by phenol extraction and ethanol precipitation.
Identification of biallelic polymorphism in the 4th intron
Using the MspI restriction enzyme, which recognises the sequence 5Ј C/CGG 3Ј, a two-allele polymorphism with fragments of either 6.3 kb or 2.6 and 3.9 kb in length has been identified. 9 On the basis of a genomic map of the IL-6 gene encompassing nucleotides 1 to 5961 (Genbank Nucleotide Query accession Y00081), 5 we have identified five potential MspI cutting sites at positions: 1178/9, 1178/9, 1387/8, 1618/9 and 1893/9 respectively. We have assumed that the next polymorphic MspI recognition site must be 2.6 or 3.9 kb downstream from the 1893/9 MspI cutting site and that, because the MspI polymorphism is not detected by other enzymes, it is likely to be due to a site-specific base pair substitution. Using the published nucleotide sequence of the IL-6 gene, and assuming that it contains one biallelic mutation of a MspI recognition site, we have searched for possible sequence candidates in the regions 2.6 ± 0.1 kb and 3.9 ± 0.1 kb, and found three potential mutation sites CCAG (4450-3), CCAG (4468-71), in the first region and one CCAG (5795-9) in the second region. All four candidates were tested by PCR-SSP (as described below) using 10 different DNA samples. One (position 4470) was polymorphic and consisted of the expected A/G substitution.
Typing biallelic and VNTR IL-6 polymorphisms
Determination of the 4470 A to G polymorphism was performed by two PCR-SSP reactions. In the first reaction, designed to detect the A allele at position 4470, we used a primer mix of antisense primer P1 (specific to A) and sense primer P3 together with control primers in the working concentrations as shown in Table 4 . In the second reaction, designed to detect the G allele at the same position, primer P1 was replaced by primer P2. The control primers amplify a 256 bp amplicon and were derived from exon 15 of the adenomatous polyposis gene. 32 The amplification of the 3Ј flanking region containing the IL-6 VNTR polymorphism was performed using a primer mix P4 and P5 (Table 4) as described by Titenko et al. 8 PCR-SSP and PCR-VNTR were carried out in a final The PCR-SSP products (13 l) with loading dye were loaded onto a 1% agarose gel containing ethidium bromide in 0.5 × TBE and electrophoresed at 4.5 V/cm for 30 min.
The PCR-VNTR products were loaded into a 2% agarose gel and electrophoresed at 100 V/cm for 3-4 h. Gels were photographed (b/w) under UV light (320 nm) (Figures 1 and 2) . Gels with PCR-SSP products were scored for the presence or absence of an allele-specific band (921 bp) when the PCR control amplicon (256 bp) was present.
Measurement of IL-6, TNF␣ and IL-10 secretion
Plasma soluble IL-6, IL-10 and TNF␣ were measured by R&D Systems ELISA kits Quantokine IL-6 (range of detection 3.12-300 pg/mL), Quantokine IL-10 (range of detection 7.8-500 pg/mL) and Quantokine TNF␣ (range of detection 15.6-1000 pg/mL) as described by the manufacturer. Plasma samples were diluted 1:200 for IL-6, 1:40 for TNF␣ and 1:20 for IL-10 with Quantokine Calibrator Dilutents. All samples were analysed in duplicate.
Statistical analysis
Results of IL-6 production are expressed as median with semi-interquartile range. Differences in cytokine production between groups were examined using the Kruskal-Wallis test. Fisher's exact test was performed for the comparison of genotypes or allele frequencies. Spearman's test was used to calculate correlation coefficients between IL-6 and IL-10 or TNF␣ production. A P value less than 0.05 was considered statistically significant.
